Download PDF
Thromb Haemost 1997; 78(01): 031-036
DOI: 10.1055/s-0038-1657496
Gene therapy for hemophilia: hopes and reality for the children of the new century
Schattauer GmbH Stuttgart

Gene Therapy for Hemophilia A

Sheila Connelly
Department of Molecular and Cell Biology, Genetic Therapy, Inc., Gaithersburg, MD, USA
,
Michael Kaleko
Department of Molecular and Cell Biology, Genetic Therapy, Inc., Gaithersburg, MD, USA
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Sadler JE, Davie EW. Hemophilia A, hemophilia B and von Willebrand’s disease. In: The Molecular Basis of Blood Diseases. Nienhuis AW, Leder P, Majerus PW. eds. W.B Saunders Co; New York: 1987. pp 575-598
    Google Scholar
  • 2 Aledort L. Inhibitors in hemophilia patients: Current status and management. Am J Hemat 1994; 47: 208-217
    CrossrefPubMedGoogle Scholar
  • 3 Lozier JN, Brinkhous KM. Gene therapy and the hemophilias. JAMA 1994; 271: 47-51
    CrossrefPubMedGoogle Scholar
  • 4 Fallaux FJ, Hoeben RC, Briët E. State and prospects of gene therapy for the hemophilias. Thromb Haemost 1995; 74: 263-273
    PubMedGoogle Scholar
  • 5 Hoeben RC. Gene therapy for the haemophilias: current status. Biologicals 1995; 23: 27-29
    CrossrefPubMedGoogle Scholar
  • 6 Smith TAG. Gene therapy for haemophilia. Exp Opin Invest Drugs 1995; 4: 833-842
    CrossrefPubMedGoogle Scholar
  • 7 Wood WI, Capon DJ, Simonsen CC, Eaton DL, Gitschier J, Keyt B, Seeburg PH, Smith DH, Hollingshead P, Wion KL, Delwart E, Tuddenham EGD, Vehar GA, Lawn RM. Expression of active human factor VIII from recombinant DNAcloned. Nature 1984; 312: 330-337
    CrossrefPubMedGoogle Scholar
  • 8 Toole JJ, Knopf JL, Wozney JM, Sultzman PA, Buecker J, Pittman DD, Kaufman RJ, Brown E, Shoemaker C, Orr EC, Amphlett GW, Foster WB, Coe ML, Knutson GJ, Fass DN, Hewick RM. Molecular cloning of a cDNA encoding antihemophiliac factor. Nature 1984; 312: 342-346
    CrossrefPubMedGoogle Scholar
  • 9 Elder B, Lakich D, Gitschier J. Sequence of the murine factor VIII cDNA. Genomics 1993; 16: 374-379
    CrossrefPubMedGoogle Scholar
  • 10 Healey JF, Lubin IM, Lollar P. The cDNA and derived amino acid sequence of porcine factor VIII. Blood 1996; 88: 4209-4214
    PubMedGoogle Scholar
  • 11 Kaufman RJ. Biological regulation of factor VIII activity. Annu Rev Med 1992; 43: 325-339
    CrossrefPubMedGoogle Scholar
  • 12 Vehar GA, Lawn RM, Tuddenham EGD, Wood WI. Factor VIII and factor V: Biochemistry and Pathophysiology. In: Biotechnology of plasma proteins. Curr Stud Hematol Blood Transf. Albertini A, Lenfant CL, Mannucci PM, Sixma JJ. eds. Karger, Basel. 1991. pp 2155-2170
    Google Scholar
  • 13 Hoyer LW, Wyshock EG, Colman RW. Coagulation Cofactors: Factors V and VIII. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW. eds. J.B Lippincott Co; Philadelphia: 1994. pp 109-133
    Google Scholar
  • 14 Eaton DL, Wood WI, Eaton D, Hass PE, Hollingshead P, Wion K, Mather J, Lawn RM, Vehar GA, Gorman C. Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. Biochem 1986; 25: 1-2
    CrossrefPubMedGoogle Scholar
  • 15 Toole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC, Kaufman RJ. A large region (_95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci USA 1986; 83: 5939-5942
    CrossrefPubMedGoogle Scholar
  • 16 Pittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ. Biochemical, Immunological, and in vivofunctional characterization of B-domain-deleted factor VIII. Blood 1993; 81: 2925-2935
    PubMedGoogle Scholar
  • 17 Dwarki VJ, Belloni P, Nijjar T, Smith J, Couto L, Rabier M, Clift S, Bems A, Cohen LK. Gene therapy for hemophilia A: Production of therapeutic levels of human factor VIII in vivo in mice. Proc Natl Acad Sci USA 1995; 92: 1023-1027
    CrossrefPubMedGoogle Scholar
  • 18 Kaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 1988; 263: 6352-6362
    PubMedGoogle Scholar
  • 19 Kaufman RJ, Wasley LC, Davies MV, Wise RJ, Israel DI, Dorner AJ. Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol Cell Biol 1989; 9: 1233-1242
    CrossrefPubMedGoogle Scholar
  • 20 Lynch CM, Israel DI, Kaufman RJ, Miller AD. Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum Gene Ther 1993; 4: 259-272
    CrossrefPubMedGoogle Scholar
  • 21 Hoeben RC, Fallaux FJ, Cramer SJ, van den Wollenberg JM, Van Ormondt H, Briët E, Van Der Eb AJ. Expression of the blood-clotting factor-VIII cDNA is repressed by a transcriptional silencer located in its coding region. Blood 1995; 85: 2447-2454
    PubMedGoogle Scholar
  • 22 Koeberl DD, Halbert CL, Krumm A, Miller AD. Sequences within the coding regions of clotting factor VIII and CFTR block transcriptional elongation. Hum Gene Ther 1995; 6: 469-479
    CrossrefPubMedGoogle Scholar
  • 23 Chuah MKL, Vandendriessche T, Morgan RA. Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A. Hum Gene Ther 1995; 6: 1363-1377
    CrossrefPubMedGoogle Scholar
  • 24 Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990; 10: 4239-4242
    CrossrefPubMedGoogle Scholar
  • 25 Hoeben RC, van der Jagt RC, Schoute F, Van Tilburg NH, Verbeet MP, Briët E, Van Ormondt H, Van Der Eb AJ. Expression of functional factor VIII in primary human skin fibroblasts after retrovirus-mediated gene transfer. J Biol Chem 1990; 265: 7318-7323
    PubMedGoogle Scholar
  • 26 Hoeben RC, Einerhand MP, Briët E, Van Ormondt H, Valerio D, Van Der Eb AJ. Toward gene therapy in haemophilia A: Retrovirus-mediated transfer of a factor VIII gene into murine haematopoietic progenitor cells. Thromb Haemost 1992; 67: 341-345
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Hoeben RC, Fallaux FJ, Van Tilburg NH, Cramer SJ, Van Ormondt H, Briët E, Van Der Eb AJ. Toward gene therapy for hemophilia A: long-term persistence of factor VIII-secreting fibroblasts after transplantation into immunodeficient mice. Hum Gene Ther 1993; 4: 179-186
    CrossrefPubMedGoogle Scholar
  • 28 Israel DI, Kaufman RJ. Retroviral-mediated transfer and amplification of a functional human factor VIE gene. Blood 1990; 75: 1074-1080
    PubMedGoogle Scholar
  • 29 Krall WJ, Skelton DC, Yu X, Riviere I, Lehn P, Mulligan RC, Kohn DB. Increased levels of spliced RNA account for augmented expression from the MFG retroviral vector in hematopoietic cells. Gene Ther 1996; 3: 37-48
    PubMedGoogle Scholar
  • 30 Zatloukal K, Cotten M, Berger M, Schmidt W, Wagner E, Birnstiel ML. In vivo production of human factor VIE in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery. Proc Natl Acad Sci USA 1994; 91: 5148-5152
    CrossrefPubMedGoogle Scholar
  • 31 Brauker JH, Carr-Brendel VE, Martinson LA, Crudele J, Johnston WD, Johnson RC. Neovascularization of synthetic membranes directed by membrane microarchitecture. J Biomed Mater Res 1995; 29: 1517-1524
    CrossrefPubMedGoogle Scholar
  • 32 Brauker J, Dwarki V, Carr-Brendel V, Nijjar T, Vergoth C, Chen R, Cohen L, Danos O, Mulligan R, Johnson RC. Expression of human factor IX in rats and mice from cells implanted within an immunoisolation device. [Abstract] J Cell Biochem 1995; suppl 21A 375
    PubMedGoogle Scholar
  • 33 Berkner KL. Development of adenovirus vectors for the expression of heterologous genes. Biotechniques 1988; 6: 616-629
    PubMedGoogle Scholar
  • 34 Trapnell BC, Gorziglia M. Gene therapy using adenoviral vectors. Curr Opin Bio tech no1 1994; 5: 617-625
    PubMedGoogle Scholar
  • 35 Connelly S, Smith TAG, Dhir G, Gardner JM, Mehaffey MG, Zaret KS, McClelland A, Kaleko M. In vivo gene delivery and expression of physiological levels of functional human factor VIE in mice. Hum Gene Ther 1995; 6: 185-193
    CrossrefPubMedGoogle Scholar
  • 36 Connelly S, Gardner JM, McClelland A, Kaleko M. High level tissue-specific expression of functional human FVIII in mice. Hum Gene Ther 1996; 7: 183-195
    CrossrefPubMedGoogle Scholar
  • 37 Connelly S, Gardner JM, Lyons RM, McClelland A, Kaleko M. Sustained expression of therapeutic levels of human factor VIE in mice. Blood 1996; 87: 4671-4677
    PubMedGoogle Scholar
  • 38 Connelly S, Mount J, Mauser A, Gardner JM, Kaleko M, McClelland A, Lothrop CD. Complete short-term correction of canine hemophilia A by in vivo gene therapy. Blood 1996; 88: 3846-3853
    PubMedGoogle Scholar
  • 39 Smith TAG, Mehaffey MG, Kayda DB, Saunders JM, Yei S, Trapnell BC, McClelland A, Kaleko M. Adenovirus-mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet 1993; 5: 397-402
    CrossrefPubMedGoogle Scholar
  • 40 Tinlin S, Webster S, Giles AR. The development of homologous (canine/anti-canine) antibodies in dogs with haemophilia A (factor VIE deficiency): A ten-year longitudinal study. Thrombosis and Haemostasis 1993; 69: 21-24
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Bi L, Lawler AM, Antonarakis SE, High KA, Gerhart JD, Kazazian HH. Targeted disruption of the mouse factor VIE gene produces a model of haemophilia A. Nature Genetics 1995; 10: 119-121
    CrossrefPubMedGoogle Scholar
  • 42 Dorner AJ, Bole DG, Kaufman RJ. The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins. J Cell Biol 1987; 105: 2665-2674
    CrossrefPubMedGoogle Scholar
  • 43 Yang Y, Ertl HCJ, Wilson JM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with El-deleted recombinant adenoviruses. Immun 1994; 1: 433-442
    CrossrefPubMedGoogle Scholar
  • 44 Yang Y, Nunes FA, Berencsi K, Furth EE, Gönczöl E, Wilson JM. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411
    CrossrefPubMedGoogle Scholar
  • 45 Armentano D, Sookdeo CC, Hehir KM, Gregory RJ, StGeorge JA, Prince GA, Wadsworth SC, Smith AE. Characterization of an adenovirus gene transfer vector containing an E4 deletion. Hum Gene Ther 1995; 6: 1343-1353
    CrossrefPubMedGoogle Scholar
  • 46 Wang Q, Jia X, Finer MH. A packaging cell line for pro-pagation of recombinant adenovirus vectors containing two lethal gen-region deletions. Gene Therapy 1995; 2: 775-783
    PubMedGoogle Scholar
  • 47 Yeh P, Dedieu JF, Orsini C, Vigne E, Denefie P, Perricaudet M. Efficient dual transcomplementation of adenovirus El and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J Virol 1996; 70: 559-565
    PubMedGoogle Scholar
  • 48 Gao G, Yang Y, Wilson JM. Biology of adenovirus vectors with El and E4 deletions for liver-directed gene therapy. J Virol 1996; 70: 8934-8943
    PubMedGoogle Scholar
  • 49 Gorziglia MI, Kadan MJ, Yei S, Lim J, Lee GM, Luthra R, Trapnell BC. Elimination of both El and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy. J Virol 1996; 6: 4173-4178
    PubMedGoogle Scholar
  • 50 Kochanek S, Clemens PR, Mitani K, Chen H, Chan S, Caskey CT. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci USA 1996; 93: 5731-5736
    CrossrefPubMedGoogle Scholar
  • 51 Clemens PR, Kochanek S, Sunada Y, Chan S, Chen H, Campbell KP, Caskey CT. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Therapy 1996; 3: 965-972
    PubMedGoogle Scholar
  • 52 Lieber A, He C, Kirillova I, Kay MA. Recombinant adenoviruses with large deletions generated by cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo . J Virol 1996; 70: 8944-8960
    PubMedGoogle Scholar
  • 53 Haecker SE, Stedman HH, Balice-Gordon RJ, Smith DBJ, Greelish JP, Mitchell MA, Wells A, Sweeney HL, Wilson JM. In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. HGT 1996; 7: 1907-1914
    PubMedGoogle Scholar
  • 54 Kumar-Singh R, Chamberlain JS. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum Mol Gen 1996; 5: 913-921
    CrossrefPubMedGoogle Scholar
  • 55 Smith TAG, White BD, Gardner JM, Kaleko M, McClelland A. Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Therapy 1996; 3: 496-502
    PubMedGoogle Scholar
  • 56 Yang Y, Trinchieri G, Wilson JM. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Medicine 1995; 1: 890-893
    CrossrefPubMedGoogle Scholar
  • 57 Yang Y, Greenough K, and Wilson JM. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Therapy 1996; 3: 412-420
    PubMedGoogle Scholar
  • 58 Bosch A, McCray PB, Chang SMW, Ulich TR, Simonet WS, Jolly DJ, Davidson BL. Proliferation induced by keratinocyte growth factor enhances in vivo retroviral-mediated gene transfer to mouse hepatocytes. J Clin Invest 1996; 98: 2683-2687
    CrossrefPubMedGoogle Scholar
  • 59 Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267
    CrossrefPubMedGoogle Scholar
  • 60 Naldini L, Blomer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996; 93: 11382-11388
    CrossrefPubMedGoogle Scholar
  • 61 Scharfmann R, Axelrod JH, Verma IM. Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proc Natl Acad Sci USA 1991; 88: 4626-4630
    CrossrefPubMedGoogle Scholar
  • 62 Palmer TD, Rosman GJ, Osborne WR, Miller AD. Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc Natl Acad Sci U S A 1991; 88: 1330-1334
    CrossrefPubMedGoogle Scholar
  • 63 Corbeau P, Kraus G, Wong-Stall F. Efficient gene transfer by a human immunodeficiency virus type 1 (HlV-l)-derived vector utilizing a stable HIV packaging cell line. Proc Natl Acad Sci USA 1996; 93: 14070-14075
    CrossrefPubMedGoogle Scholar
  • 64 Kotin RM. Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum Gene Ther 1994; 5: 793-801
    CrossrefPubMedGoogle Scholar
  • 65 Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996; 70: 8098-8108
    PubMedGoogle Scholar
  • 66 McCown TJ, Xiao X, Li J, Breese GR, Samulski RJ. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res 1996; 713: 099-107
    CrossrefPubMedGoogle Scholar
  • 67 Gnatenki D, Hearing P, Gergel J, Jesty J, Bahou W. Generation and characterization of recombinant adeno-associated viral (rAAV) vectors for factor VIII gene therapy. [Abstract] Blood 1996; 88: 139
    PubMedGoogle Scholar
  • 68 Wu GY, Wu CH. Receptor-mediated gene delivery and expression in vivo . J Biol Chem 1988; 263: 14621-14624
    PubMedGoogle Scholar
  • 69 Perales JC, Ferkol T, Beegen H, Ratnoff OD, Hanson RW. Gene transfer in vivo: Sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc Natl Acad Sci USA 1994; 91: 4086-4090
    CrossrefPubMedGoogle Scholar
  • 70 Ill CR, Yang CO, Bidlingmaier SM, Gonzales JN, Bartholomew RM, Scuderi P. Engineering the human factor VIII cDNA for targeted gene therapy. [Abstract] Thromb Haemost. 1997. ISTH:in press
    Google Scholar